NASDAQ:TRVI Trevi Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Trevi Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.02 0.00 (0.00 %) (As of 09/29/2020 04:30 PM ET) Add Compare Share Today's Range$3.89Now: $4.02▼$4.1050-Day Range$3.50MA: $4.27▼$6.6052-Week Range$1.33Now: $4.02▼$8.50Volume51,772 shsAverage Volume82,612 shsMarket Capitalization$73.32 millionP/E RatioN/ADividend YieldN/ABeta0.11 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. Trevi Therapeutics, Inc. was founded in 2011 and is headquartered in New Haven, Connecticut.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingTrevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Trevi Therapeutics has a forecasted upside of 173.6% from its current price of $4.02.Amount of Analyst CoverageTrevi Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesTrevi Therapeutics has received 46 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTrevi Therapeutics has received 61 “underperform” votes. (Add your “underperform” vote.)Community SentimentTrevi Therapeutics has received 57.01% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Trevi Therapeutics and other stocks. Vote “Outperform” if you believe TRVI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TRVI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTrevi Therapeutics does not currently pay a dividend.Dividend GrowthTrevi Therapeutics does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Trevi Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders47.30% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions73.33% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Trevi Therapeutics are expected to decrease in the coming year, from ($2.14) to ($2.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevi Therapeutics is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevi Therapeutics is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTrevi Therapeutics has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.50 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TRVI Previous Symbol CUSIPN/A CIKN/A Webwww.trevitherapeutics.com Phone203-304-2499Debt Debt-to-Equity Ratio0.01 Current Ratio6.85 Quick Ratio6.85Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.06 per share Price / Book1.31Profitability EPS (Most Recent Fiscal Year)($2.28) Net Income$-26,050,000.00 Net MarginsN/A Return on Equity-58.90% Return on Assets-52.38%Miscellaneous Employees15 Outstanding Shares18,240,000Market Cap$73.32 million Next Earnings Date11/12/2020 (Estimated) OptionableNot Optionable $4.02 0.00 (0.00 %) (As of 09/29/2020 04:30 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive TRVI News and Ratings via Email Sign-up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Trevi Therapeutics (NASDAQ:TRVI) Frequently Asked Questions How has Trevi Therapeutics' stock been impacted by Coronavirus? Trevi Therapeutics' stock was trading at $3.18 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TRVI shares have increased by 26.4% and is now trading at $4.02. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Trevi Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Trevi Therapeutics. When is Trevi Therapeutics' next earnings date? Trevi Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020. View our earnings forecast for Trevi Therapeutics. How were Trevi Therapeutics' earnings last quarter? Trevi Therapeutics Inc (NASDAQ:TRVI) announced its earnings results on Thursday, August, 13th. The company reported ($0.41) EPS for the quarter, topping the Zacks' consensus estimate of ($0.51) by $0.10. View Trevi Therapeutics' earnings history. What price target have analysts set for TRVI? 4 analysts have issued 12-month target prices for Trevi Therapeutics' stock. Their forecasts range from $9.00 to $13.00. On average, they anticipate Trevi Therapeutics' stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 173.6% from the stock's current price. View analysts' price targets for Trevi Therapeutics. Are investors shorting Trevi Therapeutics? Trevi Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 78,400 shares, an increase of 185.1% from the August 31st total of 27,500 shares. Based on an average trading volume of 103,500 shares, the days-to-cover ratio is currently 0.8 days. Currently, 2.7% of the company's shares are short sold. View Trevi Therapeutics' Short Interest. Who are some of Trevi Therapeutics' key competitors? Some companies that are related to Trevi Therapeutics include Aldeyra Therapeutics (ALDX), Urovant Sciences (UROV), Cassava Sciences (SAVA), VYNE Therapeutics (VYNE), Concert Pharmaceuticals (CNCE), Osmotica Pharmaceuticals (OSMT), Agile Therapeutics (AGRX), Xeris Pharmaceuticals (XERS), Selecta Biosciences (SELB), Affimed (AFMD), Liminal BioSciences (LMNL), Chiasma (CHMA), Paratek Pharmaceuticals (PRTK), Arbutus Biopharma (ABUS) and ProQR Therapeutics (PRQR). View all competitors. What other stocks do shareholders of Trevi Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trevi Therapeutics investors own include Trevena (TRVN), Diffusion Pharmaceuticals (DFFN), Fulcrum Therapeutics (FULC), Genocea Biosciences (GNCA), TapImmune (MRKR), VYNE Therapeutics (VYNE), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), AzurRx BioPharma (AZRX) and Chimerix (CMRX). Who are Trevi Therapeutics' key executives? Trevi Therapeutics' management team includes the following people: Ms. Jennifer L. Good, Co-Founder, CEO, Pres & Director (Age 54)Mr. Thomas R. Sciascia, Co-Founder and Chief Medical Officer (Age 66)Mr. Christopher J. Seiter, Chief Financial Officer (Age 52)Dr. Helena Brett-Smith M.D., Chief Devel. Officer (Age 62)Dr. Amale Hawi, Sr. VP of CMC (Age 65) When did Trevi Therapeutics IPO? (TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager. What is Trevi Therapeutics' stock symbol? Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI." How do I buy shares of Trevi Therapeutics? Shares of TRVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Trevi Therapeutics' stock price today? One share of TRVI stock can currently be purchased for approximately $4.02. How big of a company is Trevi Therapeutics? Trevi Therapeutics has a market capitalization of $73.32 million. The company earns $-26,050,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. Trevi Therapeutics employs 15 workers across the globe. What is Trevi Therapeutics' official website? The official website for Trevi Therapeutics is www.trevitherapeutics.com. How can I contact Trevi Therapeutics? Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The company can be reached via phone at 203-304-2499 or via email at [email protected] This page was last updated on 9/29/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
